MK-801抑制福尔马林实验引起的大鼠脊髓背角环氧合酶-2的表达

应用免疫组织化学方法,观察鞘内注射N-methyl—D—aspartate(NMDA)受体拮抗剂MK-801对福尔马林实验引起的大鼠脊髓背角环氧合酶-2(cyclooxygenase-2,COX-2)表达的影响。结果表明：MK-801对福尔马林实验引起的第1相缩足反射仅有一定抑制作用,但对第2相缩足反射有显著的抑制作用,且呈剂量依赖性。与这种行为学的变化相对应,MK-801可显著抑制福尔马林实验引起的脊髓背角COX-2表达的增加,并且这种抑制作用与MK-801的剂量呈正相关。这些结果表明,在福尔马林实验中,NMDA受体的活动是引起脊髓背角COX-2表达增加的原因之一。     

磷酸化钙/钙调蛋白依赖性蛋白激酶Ⅱ在大鼠脊髓背角C-纤维诱发电位长时程增强的诱导和维持中的作用

实验旨在探讨钙/钙调蛋白依赖性蛋白激酶II(calcium／calmodulin-dependent protein kinase Ⅱ,CaMKⅡ)在脊髓背角C-纤维诱发电位长时程增强(long—term potentiation,LTP)的诱导和维持中的作用。用Western blot技术分别检测LTP形成30min和3h脊髓背角(L4-L6)CaMKⅡ的含量及其磷酸化水平。同时观察脊髓局部给予CAMKⅡ选择性抑制剂KN-93后对脊髓背角LTP和CaMKII磷酸化的影响。观察结果如下：(1)诱导LTP后30min,CaMK Ⅱ的磷酸化水平明显高于对照组,而CaMKⅡ的总量无变化;诱导LTP后3h CaMKⅡ的磷酸化水平进一步升高。而且CaMKⅡ的总量也明显增加(n=4);(2)强直刺激前30min于脊髓局部给予CaMKⅡ的特异性抑制剂KN-93(100μmol/L),可阻断LTP的诱导,同时明显抑制CaMKⅡ的磷酸化水平;(3)诱导LTP后30min给予KN-93,可显著抑制LTP的维持,同时CaMKⅡ的磷酸化水平与未用药组相比也明显降低（n=3);(4)LTP3h后给予KN-93,LTP的幅值不受影响,磷酸化的CaMKⅡ的含量与用药前相比也无差别（n=3)。根据上述实验结果可以认为,CaMKⅡ的激活参与脊髓背角C-纤维诱发电位LTP的诱导和早期维持过程。     

急性神经损伤引起脊髓背角C-纤维诱发电位长时程增强

神经损伤引起神经病性疼痛,表现为持续性痛超敏和痛觉过敏。目前对神经病性疼痛的机制尚缺乏了解。我们以往的工作表明强直电刺激坐骨神经可引起脊髓背角C-纤维诱发电位的长时程增强(long-term potentiation,LTP),该LTP被认为是病理性疼痛的突触模型。本研究的目的在于探讨急性神经损伤是否能在完整动物的脊髓背角诱发出C-纤维诱发电位LTP。在以测试刺激(10～20V,0．5ms)电刺激坐骨神经的同时在脊髓背角用微电极记录C一纤维诱发电位。分别用强直刺激、剪断或夹捏坐骨神经诱导LTP。结果发现：(1)剪断或夹捏坐骨神经都可以诱导脊髓背角C-纤维诱发电位的LTP,该LTP可持续到实验结束(3～9h),在剪断神经前10min用利多卡因局部阻滞坐骨神经则可完全阻断LTP的产生;(2)神经损伤诱导的LTP可被NMDA受体阻断剂AP5所阻断;(3)用单次强直刺激引起LTP后,切断坐骨神经可使LTP的幅度进一步增大,而用多次强直电刺激使LTP饱和后,损伤神经则不能使LTP进一步增大。切断神经引起LTP后,强直电刺激也不能使LTP进一步增大。这些结果表明,急性神经损伤可以诱导脊髓背角C纤维诱发电位LTP,且切断神经能更有效地诱导LTP。该试验进一步支持我们的设想,即脊髓背角C-纤维诱发电位LTP可能在病理性疼痛的形成中起重要作用。     

M受体对吗啡戒断大鼠脊髓和脑干NMDA受体基因表达及中脑导水管周围灰质中谷氨酸释放的调节

应用鞘内注射反义寡脱氧核苷酸技术和RT—PCR反应,观察毒蕈碱型乙酰胆碱受体(muscarinic acetylcholine receptor,M)对吗啡依赖大鼠脊髓和脑干NMDA受体NR1A和NR2A mRNA表达和中脑导水管周围灰质区(periaqueductal grey,PAG)中谷氨酸释放的影响。结果显示,吗啡依赖大鼠脊髓NR1A和NR2A mRNA表达明显升高,而脑干中NR1A和NR2A mRNA表达没有显著变化;注射纳洛酮后1h,吗啡戒断大鼠脊髓和脑干中NR1A和NR2A表达显著高于依赖组,经NMDA受体拮抗剂MK801(0．125mg／kg,i．p．)、M受体拮抗剂东莨菪碱(0．5mg／kg,i．p．)、M1受体拮抗剂呱伦西平(10mg/kg,i．p．)和NOS抑制剂L-NAME(10mg／kg,i．p．)处理后,脊髓和脑干中NR1A和NR2A基因表达都较戒断组明显减少。在纳洛酮激发前24h鞘内注射NR1A和M2受体的反义寡脱氧核苷酸(4μg／只),戒断症状评分值及脊髓和脑干的NR1A mRNA的表达均较对照组明显减少。吗啡依赖大鼠在纳洛酮注射前24h鞘内注射M2受体反义寡脱氧核苷酸(4μg/只),可以明显减少PAG内透析液中谷氨酸含量。上述结果提示：NMDA受体的基因表达和谷氨酸释放参与吗啡戒断过程,而这种表达受到M受体的调节。     

皮质酮对原代培养海马神经元的毒性作用及NMDA受体亚基表达的改变

目的研究皮质酮对大鼠海马神经元的毒性作用及NMDA受体亚基表达的影响.方法以体外原代培养的大鼠海马神经元为研究对象,根据影响因素,即给予的不同浓度皮质酮和其它因素分为8个组:对照组、10-7mol/L皮质酮组(简称10-7组)、10-6mol/L皮质酮组(简称10-6组)、10-5mol/L皮质酮组(简称10-5组)、10-6 高糖组、10-5 高糖组、10-6mol/L MK801组和10-5mol/L MK801组,镜下观察不同浓度皮质酮作用下海马神经元形态学的变化,并采用MTT方法测量各组细胞存活率,利用免疫细胞化学结合图象分析对原代培养海马神经元NMDA受体亚基的表达进行观察.结果 10-6、10-5浓度的皮质酮对海马神经元影响较大,细胞存活率较对照组明显降低,但10-6 高糖组、 10-5mol/L 高糖组、10-6mol/L MK801及10-5mol/L MK801 4个组,分别与相同皮质酮浓度处理组比较,细胞存活率显著提高.10-6和10-5组海马神经元上NMDA受体亚基表达较对照组明显降低.10-7mol/L浓度的皮质酮对上述指标影响不大.结论过量的皮质酮对大鼠海马神经元具有损伤作用,NMDA受体参与了此过程,NMDA受体拮抗剂和高浓度葡萄糖可保护海马神经元.     

褪黑素对大鼠海马 CA3区长时程增强诱导的影响

目的：研究褪黑素对海马CA3区长时程增强（LTP）诱导阶段的影响及可能的机制。方法：用细胞外电生理记录方法。通过向大鼠海马CA3区分别微量注射褪黑素、Tacrine（胆碱酯酶抑制剂）和DNQX（非NMDA受体的竞争性拮抗剂）,以海马CA3区群体兴奋性突触后电位（fEPSP）斜率的改变为指标,观察PP-CA3通路的LTP变化。结果：①0．2μg/μl、1μg/μl和5μg/μl的褪黑素对CA3区的诱发电位和LTP均有抑制作用,随着剂量加大,抑制作用加强。②褪黑素能抑制Tacrine对LTP诱导的易化作用。③DNQx能部分阻断褪黑素对LTP诱导的抑制作用。结论：褪黑素对LTP诱导的抑制作用可能与胆碱能系统和非NMDA受体有关。     

NMDA受体介导脑缺血/再灌注诱导GluR6 巯基亚硝基化的研究

目的:研究脑缺血再灌注以及联合给予脑缺血和NMDA(N-甲基-D-天冬氨酸)受体抑制剂MK801对大鼠海马CA1区Glu R6巯基亚硝基化以及海马CA1区锥体细胞凋亡的影响。方法:采用四动脉结扎法构建大鼠全脑缺血再灌注模型,给予SD大鼠腹腔注射NMDA受体特异性抑制剂MK801(3 mg/kg)。主要运用'生物素转化法'(Biotin-Switch method)、SDS-PAGE、免疫印迹、焦油紫染色等方法对Glu R6的巯基亚硝基化(S-亚硝基化)、蛋白表达水平以及海马CA1区锥体细胞的凋亡水平进行研究。结果:脑缺血/再灌注显著促进Glu R6的巯基亚硝基化以及海马CA1区锥体细胞的凋亡,给予NMDA受体特异性抑制剂MK801能够显著抑制脑缺血/复灌诱导增加的Glu R6的S-亚硝基化以及海马CA1区锥体细胞的凋亡。结论:脑缺血/再灌注早期NMDA受体介导了Glu R6的巯基亚硝基化以及海马CA1区锥体细胞的凋亡,从而为临床治疗缺血再灌注脑损伤提供了理论依据。     

PAF受体在铝抑制海马CA3区长时程增强中的作用

目的 :观察PAF受体在铝抑制海马CA3区长时程增强 (longtermpotentiation ,LTP)中的作用。 方法 :应用细胞外电生理记录方法 ,通过向海马CA3区分别微量注射血小板活化因子 (PlateletactivatingfactorPAF)受体拮抗剂银杏内酯B(GinkgolideB)和激动剂mc PAF ,以群体锋电位 (populationspikesPS)幅度为指标 ,观察PP CA3通路的LTP变化。结果 :① 0 .2 μmol/L的银杏内酯B对CA3区的诱发电位无影响 ,但可抑制CA3区的LTP。② 0 .2 5mol/L的三氯化铝不影响CA3区LTP ,但可加强银杏内酯B的抑制作用。③ 4 0 μmol/Lmc PAF对强直刺激引起的LTP无影响 ,却可减轻 0 .5mol/L三氯化铝的对LTP的抑制作用。结论 :PAF受体在刺激PP诱发的CA3区LTP中起作用 ,而金属铝对CA3区LTP的抑制作用至少部分与PAF受体有关。     

阻断NMDA受体可增强皮质酮对海马脑源性神经营养因子表达的抑制:cAMP反应元件结合蛋白的作用

高浓度的皮质酮可引起海马形态与功能的损伤,其中脑源性神经营养因子(brain-derived neurotrophic factor,BDNF) 表达的改变在海马形态与功能损伤中扮演重要角色。本实验的目的是观察单次皮下注射皮质酮后海马内BDNF-mRNA、前 体蛋白及成熟型蛋白表达的改变,并观察N-甲基-D-天冬氨酸(N-methyl-D-aspartate NMDA)受体阻滞剂MK801对皮质酮 作用的影响。实验结果显示,单次皮下注射皮质酮2 mg／kg,3 h后海马内BDNF mRNA、前体蛋白及成熟型蛋白的表达 均降低;MK801(0．1 mg／kg)对皮质酮的这一作用有增强效果。单独给予皮质酮或注射MK801 30 min后再给予皮质酮, 均能明显降低海马中cAMP反应元件结合蛋白(cAMP response element binding protein,CREB)的磷酸化水平,MK801与 皮质酮联用时CREB的磷酸化水平降低更为显著(与单独给予皮质酮相比,P<0．05)。实验结果提示,CREB磷酸化水平降 低可能是皮质酮引起海马BDNF表达减少的重要中间环节,阻断NMDA受体可加强皮质酮降低BDNF表达的效应。     

多巴胺对大鼠背角WDR神经元的抑制不被酚妥拉明和纳洛酮所拮抗

本实验用微电极细胞外记录方法研究了脊髓局部应用多巴胺对大鼠背角WDR神经元的抑制作用。实验在43只SD大鼠上共记录到54个WDR神经元。多巴胺的剂量从0.26×10~(-6)mol/kg-1.58×10~(-6)mol/kg逐步增加,其对伤害性经皮电刺激诱发的背角神经元后串放电的抑制作用也随之加强;0.52×10~(-6)mol/kg多巴胺的作用在给药后5min即出现,15min达高峰并在此后的25min基本维持在同一水平,这个作用可被静注多巴胺能受体拮抗剂氟哌啶(0.66×10~(-6)mol/kg)完全翻转,而不受静注酚妥拉明(2.65×10~(-6)mol/kg)和纳洛酮(1.37×10~(-6)mol/kg)影响。上述结果表明,多巴胺可能是参与脊髓水平伤害性信息传递调控的另一单胺类神经递质。     

Increased cold allodynia following intrathecal N-methyl-D-aspartate in rats with a mononeuropathy

NMDA receptors are involved in the modulation of neuropathic pain behavior and central sensitization. In vivo, this is mostly demonstrated by the use of specific antagonists such as MK801. Because studies evaluating the direct impact of spinal NMDA in neuropathic pain models are lacking, we performed a series of experiments to study the role of spinal NMDA injection on existing cold allodynia, as a measurement of neuropathic pain behavior in rodents. Intrathecal injection of NMDA resulted in an enhanced neuropathic pain behavior in CCI rats on a cold plate. The activity was present from a dose of 5 ng/rat onward and could selectively be reversed by intraperitoneal injections of doses of > or = 0.01 mg/kg MK801. These results support the regulatory role of NMDA receptors in the hypersensitivity to cold observed in neuropathic pain behavior in rodents.     

NK(1) receptor and its interaction with NMDA receptor in spinal c-fos expression after lower urinary tract irritation

The role of neurokinin 1 (NK(1)) receptor and possible interaction between NK(1) and N-methyl-D-aspartic acid (NMDA) glutamatergic receptors were investigated on spinal c-fos expression after lower urinary tract irritation with acetic acid infusion in rats. At both levels of the first (L(1)) and sixth lumbar (L(6)) spinal cord, where most of hypogastric nerve and pelvic nerve afferent terminals project, respectively, the selective NK(1) receptor antagonist CP-99,994 dose dependently reduced the total number of c-fos protein (Fos)-positive cells. However, CP-100,263, the enantiomer of CP-99,994 with a very low affinity for NK(1) receptor, did not have any effect on the total number of Fos-positive cells. Coadministration of a low dose (1 mg/kg) of CP-99,994 and NMDA receptor antagonist (MK-801), either of which alone did not affect c-fos expression, significantly inhibited c-fos expression at both levels of the spinal cord. Regarding regional differences, the number of Fos-positive cells decreased significantly at all regions of the L(6) level, but only at the dorsal horn of the L(1) level. These results indicate that NK(1) receptor is involved in spinal c-fos expression after lower urinary tract irritation and that NK(1) and NMDA receptors have a synergistic interaction in the spinal processing of nociceptive input from the lower urinary tract.     

Interaction between GABAergic anticonvulsants and the NMDA receptor antagonist MK 801 against MES- and picrotoxin-induced convulsions in rats

The interaction between GABAergic (barbiturates, diazepam, ethanol) and other (phenytoin) anticonvulsants and the N-methyl-D-aspartate (NMDA) receptor antagonist MK 801 in protecting rats against maximal electroshock (MES)- and picrotoxin-induced (10 mg/kg) convulsions was studied. MK 801 (0.1 to 5 mg/kg) showed anticonvulsant responses against MES-induced convulsions in a dose dependent manner, higher doses showing severe muscle relaxation, motor incoordination, and anticonvulsant action. It also produced stereotypic head movement, circling behavior, and affected locomotion. When subanticonvulsant dose (1 mg/kg) of MK 801 was simultaneously administered with subprotective doses of GABAergic anticonvulsants, it significantly potentiated the effects of barbiturates, as compared to other agents. At 1 mg/kg, MK 801 did not offer protection against tonic convulsions though protected (100%) the animals from mortality due to picrotoxin-induced convulsions. It potentiated the effect of a subprotective dose (5 mg/kg) of pentobarbital, but not of diazepam, against tonic convulsions. However, no mortality was observed in either group. The antiglutamate action of barbiturates, particularly that of pentobarbital, may contribute to the observed potentiating response between pentobarbital and MK 801.     

Effects of ionotropic glutamate receptor channel blockers on the development of audiogenic seizures in Krushinski-Molodkina rats

The action of noncompetitive blockers of glutamate receptors has been investigated on Krushinski-Molodkina rats genetically-prone to audiogenic seizures. The selective blockers of NMDA receptor channels, memantine and IEM-1921, and their dicationic homologues, IEM-1925 and IEM-1754, capable of blocking in varying degrees both NMDA and Ca-permeable AMPA receptor channels, were studied. The drugs were injected intramuscularly to rats with the different time intervals (30 min, 1, 2 or 3 hours) before sound signal. The effects of the drugs on latent period of initial locomotor activity provoked by audio stimulation (8 kHz sine-wave tone, 90 dB volume), the appearance of clonic convulsions of different intensities, and, finally, tonic convulsions with limb and tail extension were evaluated. Within 30 min after injection IEM-1921 at a dose of 5 mg/kg, 33% of rats manifested a complete absence of convulsive reactions to sound, and in 59% of rats audiogenic seizures occured only in the form of motor excitation without a generalized clonic-tonic convulsions. Memantine at a dose of 5 mg/kg did not cause a complete blockade of seizures, but after 1 h of injection in 50% of the rats and after 2 h in 70% of rats a weakening of the audiogenic seizures to the level of motor excitation only was observed. After 3 hrs after administration of blockers its anticonvulsive action weakened significantly (p < 0.01). Dicationic blockers that block both NMDA and AMPA/kainate receptors, IEM-1925 (in doses of 0.001-20.0 mg/kg) and IEM-1754 (0.025-50.0 mg/kg), did not affect audiogenic clonic-tonic convulsive reactions. The involvement of activation of NMDA and calcium permeable AMPA/kainate receptors in the pathogenesis of audiogenic seizures is discussed.     

Effect of NMDA-receptor ligands on neocortical and hippocampal EEG activity of rat brain.

Neocortex and hippocampus play important role in motor activity, neuronal plasticity and learning and memory mechanisms. Electroencephalographic (EEG) activity of neocortex and hippocampus of rat following NMDA-receptor agonist, N-methyl-D-aspartate (NMDA), 0.25-2 nmol in 10 microliters, ICV and noncompetitive NMDA-receptor antagonists, MK 801 (0.025-0.1 mg/kg, ip) and ketamine (10-50 mg/kg, ip) at OH, 1/2H, 4H, 8H and 24H was recorded. The electrodes were implanted stereotaxically in hippocampus and neocortex respectively. NMDA (0.25 and 1 nmol) showed longer lasting decrease in amplitude in hippocampus and in frequency in cortical neurons while 2 nmol produced epileptogenic neurotoxicity. Opposite effect i.e. increase in amplitude in both, hippocampus and neocortex was observed with MK 801 and ketamine and these agents also showed longer lasting influence. Administration of MK 801 (0.05 mg/kg) and ketamine (50 mg/kg) prior to NMDA 2 nmol protected 40% animals from NMDA-induced neurotoxicity and blockade of NMDA-induced long term influence. The EEG effect of NMDA agonist and NMDA-induced neurotoxicity at higher dose and its modification by NMDA-antagonist, MK 801 and ketamine suggest that beside NMDA agonists (NMDA), its antagonists may, also affect long lasting changes in hippocampus and cortex. These antagonists reverse NMDA-mediated long term influence in these brain areas.